Drugs / Envolizumab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06876844 | Dec 2024 → Sep 2027 expected | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
| Phase 2 | NCT06143579 | Dec 2023 → Mar 2025 overdue | hepatocellular carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05911425 | Jul 2023 → Jun 2024 | bile duct cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Envolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06143579 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT05911425 ↗ |